Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.70 |
| ▸ | ACVR1B | P36896 | 12/20 | 0.54 |
| ▸ | ACVRL1 | P37023 | 11/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.54 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347154 | 0.91 | TGFBR1 (0.70) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL8344324 | 0.91 | TGFBR1 (0.71) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16134302 | 0.87 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL5954833 | 0.87 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL8348958 | 0.87 | TGFBR1 (0.63) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL5955195 | 0.87 | TGFBR1 (0.62) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL8344363 | 0.87 | TGFBR1 (0.63) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16110716 | 0.87 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879256 | 0.86 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL30585583 | 0.86 | TGFBR1 (0.73) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | TGFBR1 3765/4885ACVR1B 3981/4885ACVRL1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.